A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
NCT06874010
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Friedreich Ataxia
Interventions
DRUG:
DT-216P2
Sponsor
Design Therapeutics, Inc.